|
WO2020109621A1
|
|
Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
|
|
WO2019224304A1
|
|
Treatment of cidp
|
|
KR20210013597A
|
|
Protein extraction method and system
|
|
KR20200038507A
|
|
Hemopexin formulation
|
|
CN110831627A
|
|
Immunoglobulin product for the treatment of chronic inflammatory demyelinating polyneuropathy
|
|
WO2018193078A1
|
|
Immunoglobulin products for use in the treatment of chronic inflammatory demyelinating polyneuropathy
|
|
US2019345229A1
|
|
Methods for affecting Salmonella infections
|
|
CN106999588A
|
|
The drug products for including immunoglobulin with increased stability
|
|
AU2015258242A1
|
|
Compositions
|
|
EP3125942A1
|
|
Nebulization of immunoglobulin
|
|
EP3016976A1
|
|
Process
|
|
US2014094411A1
|
|
Method of purifying proteins
|
|
EP2822967A1
|
|
Compositions comprising secretory-like immunoglobulins
|
|
EP2636682A1
|
|
Compositions comprising secretory-like immunoglobulins
|
|
EP2636683A1
|
|
Treatment of mucositis with Immunoglobulin
|
|
EP2636684A1
|
|
Prevention of infection
|
|
EP2636681A1
|
|
Process for enriching IgA
|
|
CN102947333A
|
|
Antibody composition
|
|
AU2011212440A1
|
|
Immunoglobulin preparation
|
|
EP2465536A1
|
|
CD89 activation in therapy
|
